Sunasia Co., Ltd. (hereinafter referred to as "SUNASIA") was founded in 2002 and is headquartered in Ningbo, Zhejiang Province. The company is a comprehensive international pharmaceutical company specializing in R&D, production and sales of APIs and intermediates, and is a member of Ningbo Pharmaceutical Industry Association. Our products cover active pharmaceutical ingredients, intermediates, nutraceuticals, veterinary products and speciality chemicals.
With more than 20 years of industry experience, SUNASIA has established long-term strategic partnerships with many domestic pharmaceutical companies, relying on factory entities to jointly develop new pharmaceutical varieties, and has developed more than ten exclusive products so far. SUNASIA makes use of its own sales advantages to do professional marketing in the global market, complement each other's advantages, and join forces to maximize scale and benefits.
SUNASIA is currently in a stage of rapid development. By the end of 2022, SUNASIA's annual sales have exceeded 30 million US dollars, firmly ranking among the important members of Ningbo International Chamber of Commerce. At the same time, SUNASIA has formed a global market layout mainly in Europe and America, supplemented by Japan and South Korea, and continues to develop and deepen in other regions.
In the future, we will continue to focus on high-end pharmaceutical products, expand CDMO and import business, and become a product and service provider with great influence in the pharmaceutical industry, a global perspective, and innovative development capabilities.
